Inclusion Criteria:

- Patients must have histologically or cytologically confirmed primary malignant brain
tumors or brain metastasis

- Patients must have had radiographically evaluable or measurable disease with standard
MR imaging, and the tumor must have an enhancing component.

- Patients may or may not have had prior surgery, radiation therapy, or chemotherapy.

- Age >18 years

- Men and women and members of all races and ethnic groups will be included.

- Life expectancy of greater than 2 weeks.

- ECOG performance status < 3.

- Ability to understand and the willingness to sign a written informed consent
document, or have a representative able to consent for the patient.

Exclusion Criteria:

- Subjects with clinically significant signs of uncal herniation

- Subjects who have a contraindication for MRI

- Subjects with known hepatic insufficiency or cirrhosis

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ferumoxytol

- Subjects with known or suspected iron overload (genetic hemochromatosis or history of
multiple transfusions)

- Patients expecting to undergo surgery between the imaging sessions. Patients may
undergo surgery at any time before the first, or after the last imaging session.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant or lactating women are excluded from this study because of possible risk to
the fetus or infant.

- Inability or unwillingness to undergo the complete series of imaging sessions.
Inability or unwillingness to return to the neuro-oncology clinic at OHSU for the one
month follow-up.

- Known immunosuppression or immunodeficiency.

- Patients with stage IV or V renal insufficiency.

- Patients may not be receiving any other investigational agents.